Sawalmeh O, et al. - This study entailed comparison between pulse oral alfacalcidol therapy and daily oral alfacalcidol therapy in terms of efficacy in suppressing parathyroid hormone (PTH) after 13 weeks of therapy in a Palestinian sample of hemodialysis patients. Furthermore, demographic and biomedical characteristics of patients that were independently associated with PTH levels, were also investigated. Researchers noted that it seemed safe and convenient to switch daily alfacalcidol therapy to thrice-weekly alfacalcidol pulse therapy, specifically for hemodialysis patients with poor compliance with treatment. The significance of monitoring and preventing malnutrition in hemodialysis patients as well as maintaining optimal glycemic control in diabetic hemodialysis patients was also highlighted in the findings.